Neuromyelitis optica spectrum disorders: Long-term safety and efficacy of rituximab in Caucasian patients

Multiple Sclerosis

Volumn 22, Issue 4, 2016, Pages 511-519

  Radaelli, M ^a   Moiola, L ^a   Sangalli, F ^a   Esposito, F ^a   Barcella, V ^a   Ferre L ^a   Rodegher, M ^a   Colombo, B ^a   Fazio, R ^a   Martinelli, V ^a   Comi, G ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Adverse effects; antibody levels; disability; efficacy; infections; neuromyelitis optica; optic neuritis; recurrent transverse myelitis; risk profile; rituximab; safety

Indexed keywords

AZATHIOPRINE; CD19 ANTIGEN; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; INTERFERON; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; RITUXIMAB; CD20 ANTIGEN; HYDROXYZINE; IMMUNOGLOBULIN G; PARACETAMOL DERIVATIVE;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; CAUCASIAN; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE INTERVAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HEPATITIS B; HUMAN; IMMUNOGLOBULIN DEFICIENCY; INFECTION; ITALY; LEUKEMIA; LEUKOCYTE COUNT; LEUKOPENIA; LIMITED MOBILITY; LONGITUDINAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MYELOOPTIC NEUROPATHY; NEUROMYELITIS OPTICA SPECTRUM DISORDER; OBSERVATIONAL STUDY; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; PNEUMONIA; PROSPECTIVE STUDY; RECURRENCE RISK; RETREATMENT; UNSPECIFIED SIDE EFFECT; CONVALESCENCE; DISABILITY; DRUG ADMINISTRATION; EPIDEMIOLOGY; ETHNOLOGY; IMMUNOLOGY; MIDDLE AGED; NEUROMYELITIS OPTICA; REMISSION; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CLINICAL TRIAL; DISEASE COURSE; DISEASE DURATION; IMMUNOSUPPRESSIVE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; SINGLE DRUG DOSE;

ADULT; AGED; DISABILITY EVALUATION; DRUG ADMINISTRATION SCHEDULE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ITALY; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; REMISSION INDUCTION; RITUXIMAB; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84962624540     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515594042     Document Type: Article

References (34)

1. Devic E,. Myélite subaiguë compliquée de névrite optique. Bull Méd 1894; 8: 1033-1034.
2. Fazio R, Radaelli M, Furlan R,. Neuromyelitis optica: Concepts in evolution. J Neuroimmunol 2011; 231: 100-104.
3. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012; 135: 1834-1849.
4. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112.
5. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805-815.
6. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473-477.
7. Bizzoco E, Lolli F, Repice AM, et al. Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol 2009; 256: 1891-1898.
8. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on the diagnosis and management of neuromyelitis optica. Eur J Neurol 2010; 17: 1019-1032.
9. Dalakas MC,. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 2008(10): 557-567.
10. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 23: 1485-1489.
11. Greco R, Bondanza A, Vago L, et al. Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. Ann Neurol 2013 Ann Neurol. 2014; 75 (3): 447-53.
12. Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 12: 1270-1272.
13. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: Retrospective analysis of 25 patients. Arch Neurol 2008; 65: 1443-1448.
14. Kim S-H, Kim W, Li XF, et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 2011; 68: 1412-1420.
15. Bedi GS, Brown AD, Delgado SR, et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 2011; 17: 1225-1230.
16. Kim S-H, Huh S-Y, Lee SJ, et al. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. J Am Med Ass Neurol 2013; 1: 1110-1117.
17. Greenberg BM, Graves D, Remington G, et al. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: Creating strategies for therapeutic success. Mult Scler 2012; 18: 1022-1026.
18. Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011; 76: 1310-1315.
19. Wingerchuk DM, Weinshenker BG,. White matter disease: Optimizing rituximab therapy for neuromyelitis optica. Nat Rev Neurol 2011; 7: 664-665.
20. Pohl M, Fischer MT, Mader S, et al. Pathogenic T-cell responses against aquaporin 4. Acta Neuropathol 2011; 122: 21-34.
21. Matsuya N, Komori M, Nomura K, et al. Increased T-cell immunity against aquaporin-4 and proteolipid protein in neuromyelitis optica. Int Immunol 2011; 23: 565-573.
22. Kim S-H, Kim W, Park MS, et al. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol 2011; 68: 473-479.
23. Cabre P, Olindo S, Marignier R, et al. Efficacy of mitoxantrone in neuromyelitis optica spectrum: Clinical and neuroradiological study. J Neurol Neurosurg Psychiatr 2013; 84: 511-516.
24. Mandler RN, Ahmed W, Dencoff JE,. Devic's neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998; 51: 1219-1220.
25. Costanzi C, Matiello M, Lucchinetti CF, et al. Azathioprine: Tolerability, efficacy and predictors of benefit in neuromyelitis optica. Neurology 2011; 77: 659-666.
26. Elsone L, Kitley J, Luppe S, et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: A multicentre retrospective observational study from the UK. Mult Scler 2014; 20: 1533-1540.
27. Bichuetti DB, Lobato de Oliveira EM, et al. Neuromyelitis optica treatment: Analysis of 36 patients. Arch Neurol 2010; 67: 1131-1136.
28. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: Retrospective analysis of 24 patients. Arch Neurol 2009; 66: 1128-1133.
29. Dörr J, Bitsch A, Schmailzl KJG, et al. Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment. Neurology 2009; 73: 991-993.
30. Martinelli V, Cocco E, Capra R, et al. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology 2011; 77: 1887-1895.
31. Casulo C, Maragulia J, Zelenetz AD,. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk 2013; 13: 106-111.
32. Francisci S, Caldora M, Capocaccia R, et al. I tumori in Italia: Rapporto 2006. [ The tumors in Italy: Report 2006 ]. Epidemiol Prev 2006; 30: 144.
33. Van Vollenhoven RF, Emery P, Bingham CO III, et al. Long-term safety of rituximab in rheumatoid arthritis: A 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013; 1: 1496-1502.
34. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: A meta-analysis. J Am Med Ass 2012; 5: 898-908.